Axxontis Biopharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 6.67%
- Profit Growth 20.31%
- Ebitda -5.91%
- Net Worth 33.73%
- Total Assets 74.69%
About Axxontis Biopharmaceuticals
Axxontis Biopharmaceuticals Private Limited (ABPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 November 2015 (Nine years and two months 19 days old ). Its registered office is in Hoshiarpur, Punjab, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vandana Sood, Sushma Kumari, and Sakshi serve as directors at the Company.
Company Details
-
Location
Hoshiarpur, Punjab, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232PB2015PTC039919
-
Company No.
039919
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Nov 2015
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Axxontis Biopharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vandana Sood
|
Director | 23-Nov-2015 | Current |
|
Sushma Kumari
|
Whole-Time Director | 23-Nov-2015 | Current |
|
Sakshi
|
Whole-Time Director | 14-Oct-2020 | Current |
Financial Performance of Axxontis Biopharmaceuticals.
Axxontis Biopharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 6.67% increase. The company also saw a substantial improvement in profitability, with a 20.31% increase in profit. The company's net worth Soared by an impressive increase of 33.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Axxontis Biopharmaceuticals?
In 2022, Axxontis Biopharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sood Medicine Traders Private LimitedVandana Sood is a mutual person
-
Axon Health Care Private Limited
Vandana Sood is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Axxontis Biopharmaceuticals?
Unlock and access historical data on people associated with Axxontis Biopharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Axxontis Biopharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Axxontis Biopharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
